Efficacy and Safety of Firocoxib for the Treatment of Pain Associated with Soft Tissue Surgery in Dogs under Field Conditions in Japan

Kondo, Yumi; Takashima, Kazuaki; Matsumoto, Satoshi; Shiba, Masahiro; Otsuki, Tomoko; Kinoshita, Gen; Rosentel, Joseph; Gross, Sheila J.; Fleishman, Candis; Yamane, Yoshihisa

doi:10.1292/jvms.11-0306

Cited by 12 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of two other NSAIDs, administered as a single oral dose pre-surgery followed by 2 days post-surgery, for the control of pain and inflammation in soft tissue surgery in dogs was investigated in the following two studies. For firocoxib, superior efficacy versus a negative control was reported with a comparable design to our study and pain assessment using the CMPS-SF [26]. The frequency of rescue therapy was 16.4% for the active and 50.0% for the negative control.…”

Section: Discussionsupporting

confidence: 62%

“…The efficacy of various NSAIDs in peri-operative pain management has been investigated previously in clinical studies in dogs [11, 12, 25, 26]. Comparison of results between studies is difficult due to different study designs, anesthetic procedures, concomitant drugs, NSAID treatment durations, types of surgeries as well as pain assessment methods.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Friton¹,

Thompson

Karadzovska

et al. 2017

BMC Vet Res

View full text Add to dashboard Cite

BackgroundNon-steroidal anti-inflammatory drugs (NSAIDs) have been proven to be effective in controlling peri-operative pain in dogs. Robenacoxib is an NSAID with high selectivity for the cyclooxygenase (COX)-2 isoform. The objective of this study was to assess the efficacy and safety of an oral tablet formulation of robenacoxib in client-owned dogs undergoing soft tissue surgery. The study was a prospective, multi-center, randomized, masked, placebo-controlled, parallel-group clinical trial. A total of 239 dogs were included and randomly allocated in a 1:1 ratio to receive either robenacoxib or placebo. Each dog received an oral tablet administration of either robenacoxib, at a target dose of 2 mg/kg, or placebo once prior to surgery and for two additional days post-operatively. All dogs also received a pre-anesthetic dose of 0.2 mg/kg butorphanol (intravenous or intramuscular). Pain assessments were performed using the short form of the Glasgow Composite Measure Pain Scale. Robenacoxib was compared to the placebo group on a success/failure basis. Treatment failure was defined as the need for rescue therapy to control post-operative pain.ResultsSignificantly (P = 0.019) more dogs administered robenacoxib were considered treatment successes (89 of 116, 76.72%) compared to dogs given placebo (74 of 115, 64.35%). The percentage of treatment failure was therefore 23.28% in the robenacoxib and 35.65% in the placebo group. The least squares mean total pain scores were significantly different between groups and in favor of robenacoxib at 3 and 5 hours (P < 0.05) and 8 hours post-extubation (P < 0.01). Pain at the surgery sites (response to touch) was also significantly improved at 3, 5 and 8 hours post-extubation in dogs receiving robenacoxib versus placebo (P < 0.01). In addition, a significant overall improvement in posture/activity was revealed with robenacoxib having lower scores versus placebo (P < 0.01). No significant differences between the robenacoxib and placebo groups in the frequency of reported adverse events were observed.ConclusionsRobenacoxib by oral (tablet) administration was effective and well tolerated in the control of peri-operative pain and inflammation associated with soft tissue surgery in dogs.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Friton¹,

Thompson

Karadzovska

et al. 2017

BMC Vet Res

View full text Add to dashboard Cite

show abstract

“…In optimally designed non-inferiority studies, the methods and outcome measures should be similar to those used in the original studies of the active control [18]. Superiority of deracoxib versus placebo, and firocoxib versus a negative control, was reported recently from two studies in dogs undergoing soft tissue using similar methods to our study including use of the GCPS [20,21]. The frequency of rescue therapy in those studies with treatment as a single dose pre-surgery followed by 2 days post-surgery was higher [deracoxib 2/16 (12.5%), placebo 9/16 (56.25%), firocoxib (16.4%), negative control (50.6%)] than in our study with robenacoxib (0%) or meloxicam (0%).…”

Section: Discussionmentioning

confidence: 94%

Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial

2013

View full text Add to dashboard Cite

BackgroundNon-steroidal anti-inflammatory drugs (NSAIDs) are used routinely to control pain and inflammation after surgery in dogs. Robenacoxib is a new NSAID with high selectivity for the cyclo-oxygenase (COX)-2 isoform of COX. The objective of this study was to evaluate the efficacy and tolerability of robenacoxib for the management of peri-operative pain and inflammation associated with soft tissue surgery in dogs. The study was a prospective, randomized, blinded, positive-controlled, non-inferiority, multi-center clinical trial. A total of 174 dogs undergoing major soft tissue surgery were included and randomly allocated in a 2:1 ratio to receive either robenacoxib (n = 118) or the positive control, meloxicam (n = 56). Each dog received an initial dose subcutaneously prior to surgery (robenacoxib 2 mg/kg, meloxicam 0.2 mg/kg), followed by daily oral doses (robenacoxib 1–2 mg/kg, meloxicam 0.1 mg/kg) for 12 days (range 10–14) after surgery. Pain and inflammation were assessed subjectively using the Glasgow Composite Pain Scale (GCPS) by clinicians as the primary end point and additional evaluations by the clinicians and animal owners as secondary endpoints.ResultsBoth treatments provided similar pain control, with no significant differences between groups for any efficacy variable using non-parametric analyses (Mann–Whitney U test). In no dog was analgesic rescue therapy administered. Non-inferior efficacy of robenacoxib compared to meloxicam was demonstrated statistically for the primary and all secondary endpoints using parametric analysis of variance, although the data were not normally distributed even after log transformation. For the primary endpoint (reciprocal of the modified GCPS score), the relative efficacy of robenacoxib/meloxicam was 1.12 with a 95% confidence interval of 0.97-1.29.Both treatments were well tolerated and did not affect buccal mucosal bleeding time.ConclusionA treatment regimen of robenacoxib by subcutaneous injection followed by oral tablets had good tolerability and non-inferior efficacy compared to meloxicam for the management of peri-operative pain and inflammation associated with soft tissue surgery in dogs.

show abstract

“…Moreover, firocoxib is effective for acute pain control in dogs in the postoperative periods [20]. However, the effects of firocoxib in feline patients are unclear [22].…”

Section: Introductionmentioning

confidence: 99%

Analgesic efficacy of oral firocoxib in ovariohysterectomized cats

Phuwapattanachart

Thengchaisri

2017

J Vet Sci

View full text Add to dashboard Cite

The postoperative analgesic effects of firocoxib in ovariohysterectomized cats were observed. Twenty-four cats were divided into 3 groups: control (no medicine), firocoxib-1 (1 mg/kg/day) and firocoxib-3 (3 mg/kg/day). Colorado pain scale scores (CPSS), composite pain scores (CPS), and buccal mucosal bleeding times (BMBT) were recorded in blinded fashion before induction and 2, 5, 8, 24, 30, and 48 h post-operation. The average CPSS (mean ± SEM) over 2 to 48 h post-operation in firocoxib-3 (0.4 ± 0.1) was significantly lower than that of the control (0.7 ± 0.2; p = 0.004), but that of firocoxib-1 (0.5 ± 0.2) was not different from that of the control (p = 0.40). The mean CPS of firocoxib-3 was significantly lower than that of the control at 24 h post-operation (p = 0.04); nonetheless, there was no significant difference in mean CPS between firocoxib-1 and control groups at all intervals. BMBT and body temperature were within normal limits in all groups. However, reversible azotemia was identified in two firocoxib-3 cats at 72 h post-operation. One firocoxib-3 cat vomited once at 48 h post-operation. In conclusion, firocoxib-3 is helpful for postoperative pain control in cats; however, gastrointestinal irritation and renal function side effects may occur.

show abstract

Efficacy and Safety of Firocoxib for the Treatment of Pain Associated with Soft Tissue Surgery in Dogs under Field Conditions in Japan

Cited by 12 publications

References 15 publications

Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial

Analgesic efficacy of oral firocoxib in ovariohysterectomized cats

Contact Info

Product

Resources

About